{"id":"e51a1cac-7542-5273-84b9-401fa0dfc397","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-human-response-heterogeneity","predicate":"variable_effect_on","statement":"Chromium did not consistently improve insulin action across the full phenotype range; response-defined subgroups differed in baseline insulin resistance and glycemia but not chromium status.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"1ed5d1a9-deed-5e87-a05e-697d50593f4b","mechanism_event_label":"Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.","subject":{"id":"1d98d864-31cb-5d4f-a587-2b0eb692faa0","slug":"chromium","display_name":"Chromium","entity_type_key":"nutrient_element"},"object":{"id":"6bb58c9a-8bd2-560e-a11b-ecf2935dd333","slug":"insulin-sensitivity","display_name":"Insulin sensitivity","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1ed5d1a9-deed-5e87-a05e-697d50593f4b","stable_key":"4d8e4781-3878-5818-8d0a-7dbd6e024555:chromium-human-response-heterogeneity-event","event_type":"observed_intervention","label":"Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.","description":"Chromium did not consistently improve insulin action across the full phenotype range; response-defined subgroups differed in baseline insulin resistance and glycemia but not chromium status.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"1d98d864-31cb-5d4f-a587-2b0eb692faa0","slug":"chromium","display_name":"Chromium","entity_type_key":"nutrient_element"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"6bb58c9a-8bd2-560e-a11b-ecf2935dd333","slug":"insulin-sensitivity","display_name":"Insulin sensitivity","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/chromium-research/20022616.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\", \"start_char\": 0, \"end_char\": 1864, \"text_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized supplementation with euglycemic-clamp and tissue-lipid substudy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"1,000 µg chromium/day or placebo; responders classified by ≥10% change in insulin sensitivity","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Response-defined subgroup comparisons can be affected by regression to the mean and post-treatment selection. They do not validate a deficiency test or a prospective rule for choosing treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Chromium research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"chromium","display_name":"Chromium","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human with type 2 diabetes across a range of phenotypes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Insulin sensitivity, muscle/liver lipid and chromium measurements","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"b3c74c2e-81f7-5dcb-b29b-52b39f1fbb7a","evidence_kind":"source_excerpt","locator":"Lines 1082-1093","start_line":1082,"end_line":1093,"excerpt":"### chromium-human-response-heterogeneity\nChromium did not consistently improve insulin action across the full phenotype range; response-defined subgroups differed in baseline insulin resistance and glycemia but not chromium status.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.\norganism: Human with type 2 diabetes across a range of phenotypes\ntissue_or_cell_type: Insulin sensitivity, muscle/liver lipid and chromium measurements\nexperimental_model: Randomized supplementation with euglycemic-clamp and tissue-lipid substudy\nlimitations: Response-defined subgroup comparisons can be affected by regression to the mean and post-treatment selection. They do not validate a deficiency test or a prospective rule for choosing treatment.\nexposure: 1,000 µg chromium/day or placebo; responders classified by ≥10% change in insulin sensitivity\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/20022616.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\", \"start_char\": 0, \"end_char\": 1864, \"text_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\"}\n[chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023","model_system":"Randomized supplementation with euglycemic-clamp and tissue-lipid substudy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"fa96342a-ca01-5425-98d9-d50e29bf0abd","stable_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"6cae22f9104c6de041b25c23b0fd2884cc57707ac0c9a87c20b0e665d16de5ab","revision_id":"22893798-8329-5295-9c9d-82169032fc79","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[{"id":"ddd59981-c30c-54e6-9baf-a5c9fdf06564","title":"Does chromium picolinate improve glycemic control in treated type 2 diabetes?","kind":"contradiction","status":"open","why":"The 1997 trial reported substantial HbA1c improvement, while the 2006 insulin-treated trial found approximately equal improvement with chromium and placebo. A smaller sulfonylurea trial reported benefit, and later work found heterogeneous responses. Dose, baseline glycemia, medication, population, analysis and study quality could contribute; no single verified mechanism explains the differences.","resolution":"Preserve the positive and null trials with their exact exposure and population. Do not infer a universal glucose-lowering effect or a chromium-deficiency diagnosis from treatment response. Community proposals should identify which difference they explain and what experiment could test it.","created_at":"2026-09-17 19:32:27","record_type":"conflict","display_label":"Recorded conflict","record_url":"/conflicts/ddd59981-c30c-54e6-9baf-a5c9fdf06564","sides":[{"conflict_id":"ddd59981-c30c-54e6-9baf-a5c9fdf06564","ordinal":0,"label":"This trial reported better long-term glucose control with chromium picolinate.","revision_id":"22893798-8329-5295-9c9d-82169032fc79","start_line":1017,"end_line":1028,"quote":"### chromium-diabetes-hba1c-positive\nAfter four months, reported HbA1c values were 8.5%, 7.5% and 6.6% in the placebo, 200 µg/day and 1,000 µg/day groups, respectively.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: This trial reported better long-term glucose control with chromium picolinate.\norganism: Human with treated type 2 diabetes\ntissue_or_cell_type: HbA1c, glucose, insulin and lipids\nexperimental_model: Randomized three-arm supplementation trial; 180 adults\nlimitations: Historical single-population trial; response does not diagnose chromium deficiency. Baseline diet, medication context and replication matter; later trials reported null effects.\nexposure: Placebo, 200 or 1,000 µg Cr/day as picolinate for four months while usual medications continued\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/9356027.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\", \"start_char\": 0, \"end_char\": 1941, \"text_sha256\": \"9c9f5146517d1c6967a6f75951c79fbb828408e96693be5df98f9fb1ec91aa69\"}\n[chromium-p9356027] Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. (1997). https://pubmed.ncbi.nlm.nih.gov/9356027/ DOI: 10.2337/diab.46.11.1786","source_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","source_title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","claim_ids":["8ab00528-f1ce-594e-ad7e-596a78cfa713"]},{"conflict_id":"ddd59981-c30c-54e6-9baf-a5c9fdf06564","ordinal":1,"label":"A later trial did not reproduce the earlier glucose-control benefit.","revision_id":"22893798-8329-5295-9c9d-82169032fc79","start_line":1056,"end_line":1067,"quote":"### chromium-diabetes-hba1c-null\nHbA1c fell by about 0.4 percentage points in all three groups, with no chromium benefit over placebo.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A later trial did not reproduce the earlier glucose-control benefit.\norganism: Human obese adults with insulin-treated type 2 diabetes\ntissue_or_cell_type: HbA1c and secondary metabolic endpoints\nexperimental_model: Six-month double-blind randomized placebo-controlled trial\nlimitations: Per-protocol analysis and selected insulin-treated population. This is a clinically relevant null result, not proof that no person can respond.\nexposure: 500 or 1,000 µg Cr/day as picolinate; baseline HbA1c >8% and insulin >50 units/day; per-protocol analysis n=46\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/16505499.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59\", \"start_char\": 0, \"end_char\": 1206, \"text_sha256\": \"bd1f6a73f70c17bce17b217555cef0c349bd27e8d2bbbe0573b826217039df59\"}\n[chromium-p16505499] Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese Western population: a randomized, double-blind, placebo-controlled trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16505499/ DOI: 10.2337/diacare.29.03.06.dc05-1453","source_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","source_title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","claim_ids":["37c03d69-7270-528c-a175-2c2a11796fed"]},{"conflict_id":"ddd59981-c30c-54e6-9baf-a5c9fdf06564","ordinal":2,"label":"This smaller trial reported benefit in a different medication setting.","revision_id":"22893798-8329-5295-9c9d-82169032fc79","start_line":1069,"end_line":1080,"quote":"### chromium-glipizide-trial-sensitivity\nThe chromium-plus-sulfonylurea group showed improved measured insulin sensitivity and glucose control compared with the study’s sulfonylurea/placebo comparison.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: This smaller trial reported benefit in a different medication setting.\norganism: Human with type 2 diabetes\ntissue_or_cell_type: Insulin sensitivity, glycated hemoglobin and body composition\nexperimental_model: Double-blind randomized trial after sulfonylurea run-in\nlimitations: Small trial with concurrent glipizide. Reported benefit does not establish chromium deficiency, isolate every mediator or generalize to other treatment populations.\nexposure: Glipizide run-in then 1,000 µg Cr/day as picolinate or placebo for six months; randomized groups n=17 and n=12\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/16873787.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c\", \"start_char\": 0, \"end_char\": 1823, \"text_sha256\": \"e8b9da2c39dd1dde1b2aba2fe7db1f7b9330d110b1594f3ee96df161840f731c\"}\n[chromium-p16873787] Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. (2006). https://pubmed.ncbi.nlm.nih.gov/16873787/ DOI: 10.2337/dc06-0254","source_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","source_title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","claim_ids":["f245439f-868d-5615-b7ef-50ec1d27d5af"]},{"conflict_id":"ddd59981-c30c-54e6-9baf-a5c9fdf06564","ordinal":3,"label":"Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.","revision_id":"22893798-8329-5295-9c9d-82169032fc79","start_line":1082,"end_line":1093,"quote":"### chromium-human-response-heterogeneity\nChromium did not consistently improve insulin action across the full phenotype range; response-defined subgroups differed in baseline insulin resistance and glycemia but not chromium status.\nCondition category: normal\nnutrient_topic: Chromium research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Not everyone responded, and the measured chromium level did not distinguish responders from nonresponders.\norganism: Human with type 2 diabetes across a range of phenotypes\ntissue_or_cell_type: Insulin sensitivity, muscle/liver lipid and chromium measurements\nexperimental_model: Randomized supplementation with euglycemic-clamp and tissue-lipid substudy\nlimitations: Response-defined subgroup comparisons can be affected by regression to the mean and post-treatment selection. They do not validate a deficiency test or a prospective rule for choosing treatment.\nexposure: 1,000 µg chromium/day or placebo; responders classified by ≥10% change in insulin sensitivity\nevidence_span: {\"source_cache\": \"artifacts/chromium-research/20022616.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\", \"start_char\": 0, \"end_char\": 1864, \"text_sha256\": \"0c9e6d805526dd6fa08c3a57f750df6d1f2312932e04ea8c3ce7975f46d65ab2\"}\n[chromium-p20022616] Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. (2010). https://pubmed.ncbi.nlm.nih.gov/20022616/ DOI: 10.1016/j.metabol.2009.09.023","source_key":"import-4d8e4781-3878-5818-8d0a-7dbd6e024555","source_title":"Chromium: transport, insulin signaling, nutrient interactions and essentiality debate (2026-09-17)","claim_ids":["e51a1cac-7542-5273-84b9-401fa0dfc397"]}]}],"corrections":[],"research":null}